News

Hospitals with lower-than-expected CDI antimicrobial use had on average fewer beds, shorter length of stay, and higher proportion of undergraduate or nonteaching medical school affiliation.

The study suggested children born extremely premature may remain "preterm for life," with ophthalmic sequelae persisting into adulthood.

New data from the NAVIGATOR study found that tezepelumab was associated with fewer asthma exacerbations throughout all seasons of the year compared to placebo.

Dr. Shrine and colleagues conducted the largest genome-wide association study of coexisting asthma and COPD to date in a 2-stage design incorporating a total of 13 studies.

Dr. Mease discusses a recent network meta-analyses that included new phase 3 data on guselkumab.

The recombinant von Willebrand factor, VONVENDI, receives approval from the FDA to treat patients living with severe type 3 von Willebrand disease.

Resmetirom is being studied as a potential treatment for both NAFLD and NASH.

The approval of the Spikevax vaccine was based on safety and efficacy data approximately 6 months after the second dose.

Rates of aspirin use for preeclampsia prophylaxis were observed in a minority of women with risk factors including pre-pregnancy diabetes, obesity, or chronic hypertension.

A new assessment of payer incentives offered through physician organizations suggest the dominating emphasis of quantity over quality in pay.

Pfizer’s statement does not include a reason for the Complete Response Letter the FDA issued regarding the Biologics License Application for somatrogon for Pediatric Growth Hormone Deficiency.

The majority of drugs in development for IBD target inflammation.

Dr. Bagel details newer topical therapies such as tapinarof and roflumilast, and speaks to how greater access to these therapies is needed among psoriasis patients.

Though continuous positive airway pressure and high-flow nasal oxygen have both been recommended for acute hypoxemic respiratory failure in patients infected with the COVID-19 virus, the effectiveness and safety of these strategies were uncertain.

Don't Miss a Beat is Practical Cardiology's expert-led podcast. The monthly podcast, which is hosted by Drs. Greene and Vaduganathan, will provide a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases.

The Carter Center announces that just 14 cases of Guinea worm disease occurred worldwide in 2021--the lowest case total ever recorded.

About 30% of patients with ulcerative colitis do not adequately respond to anti-TNF therapy.

The findings of this study can be applied to guide opioid counseling and monitoring when prescribing the medication.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

A multitude of promising new investigative therapies are on the horizon for inherited retinal disease.

YOSEMITE and RHINE data further supports the novel agent for diabetic macular edema. A study investigators explains the impact of the new findings.

Dr. Modi discusses the pending approval of faricimab for nAMD, DME treatment and highlights important observations from phase 3 data.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.

Outlook Therapeutics is expected to submit a BLA to the FDA for the investigative ophthalmic bevacizumab-vikg formulation (ONS-5010).

TENAYA and LUCERNE show reduced treatment burden in nAMD patients, while vision gains and extended durability for DME patients were observed in YOSEMITE and RHINE.

Oral CAIS had a slightly higher, but small risk of severe adverse reaction compared to topical CAIS, which may help the reluctance to prescribe.

Approximately 50% of individuals who commit suicide make a health care visit in the proceeding month.

Prior studies have predominantly considered the associations of respiratory allergy and skin allergy in patients with ADHD, with inconsistent data on food allergy.

Despite the prevalence of pulmonary exacerbations in patients with cystic fibrosis, there is no standardized definition to diagnose these events in affected patients.